Xeris Biopharma Holdings, Inc.
XERS · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.18 | -0.30 | 0.36 | -0.67 |
| FCF Yield | 1.38% | -1.20% | 0.35% | -1.98% |
| EV / EBITDA | 107.79 | 852.80 | 123.23 | -78.06 |
| Quality | ||||
| ROIC | 1.78% | -1.30% | 0.69% | -4.24% |
| Gross Margin | 79.58% | 85.48% | 84.23% | 74.95% |
| Cash Conversion Ratio | 29.68 | -0.09 | 1.09 | -0.39 |
| Growth | ||||
| Revenue 3-Year CAGR | 20.35% | 22.43% | 22.40% | 22.58% |
| Free Cash Flow Growth | 200.00% | -672.31% | 120.91% | 21.90% |
| Safety | ||||
| Net Debt / EBITDA | 23.03 | 171.26 | 34.92 | -25.97 |
| Interest Coverage | 0.61 | -0.42 | 0.22 | -1.66 |
| Efficiency | ||||
| Inventory Turnover | 0.22 | 0.17 | 0.20 | 0.30 |
| Cash Conversion Cycle | 422.94 | 547.18 | 496.23 | 317.63 |